Edimer

Diego joined VI Partners in January 2003 as a partner focusing on life-science and biotech investments. He brings over 10 years of experience in life science, medical devices and pharmaceuticals in Europe and the US. Prior to his entry into the venture capital industry, Diego held various managerial positions in the pharmaceutical and medical device sectors*, as well as in biotech start ups in Europe and the US. Diego holds an MSc in Microbiology from the Biocenter of the University of Basel and a Ph.D. in Molecular and Cellular Biology from the Swiss Cancer Research Institute (ISREC) in Lausanne.

Neil is a pharmaceutical executive with over 20 years of experience with leading biotechnology companies, including Biogen, Genetics Institute, Vertex, TKT and Stromedix. Neil has held positions of increasing responsibility in global regulatory affairs, strategic planning, portfolio management, non-clinical development, manufacturing and program management. During his career, Neil has been involved with the development, registration and successful commercial launches of several important therapeutic biopharmaceuticals (including recombinant coagulation factors, cytokines and enzyme replacement therapies). Neil received his Ph.D. in the faculty of medicine from the University of London.

Nick Leschly joined Third Rock Ventures in 2007 and plays an integral role in the overall formation, development and business strategy of therapeutic companies as well as identifying and evaluating new investments. Nick assumes active leadership roles in Third Rock's portfolio companies, functioning as interim COO/CBO through the first 12-18 months post launch. Prior to joining Third Rock, Nick served as the product and alliance leader for Millennium Pharmaceuticals VELCADE™, managing a S100M+ global development plan. Nick also founded and served as CFO of MedXtend Corporation. Nick holds a BS in Molecular Biology from Princeton University and an MBA from Wharton Business School. Nick is the Founder and Chairman of The CAVU foundation.

Phil is an accomplished entrepreneur with a long-standing interest in genetic testing and in developing new therapies for genetic diseases. Prior to joining Third Rock Ventures, Phil was the CEO and Chairman of the Board of Interteukin Genetics, Inc. and served as the Executive Director of the non-profit Eunice Kennedy Shriver Center for Mental Retardation, Inc, Phil has authored or co-authored more than 100 articles in scholarly journals and published six books. Phil holds an MD from Yale University, a JD from Columbia University, is a member of the Massachusetts Bar, and board certified in internal medicine and clinical genetics. He is currently a trustee of Cornell University. Phil also served twice (2000, 2003) as President of the American Society of Law, Medicine and Ethics, and on the Board of Directors of the American Society for Human Genetics. Phil has also held numerous teaching positions at Tufts University School of Medicine, Harvard Medical School, Cornell University, and has been an adjunct professor of both legal studies and biology at Brandeis University.